Author(s): Taapsi Johri ,Dr Deepa Kachroo Tiku

The Supreme Court of India's recent decision concerning Novartis' anti-cancer drug Glivec is certainly the most crucial decision of 2013, with far-reaching implications on pharmaceutical businesses both in India and internationally. Much has already been said on this judgment, with polarised opinions.